Nurphoto | Nurphoto | Getty Images
Cripple Thursday, reduced its procurement forecasts in the annual year, citing $ 200 million in estimated costs for prices and a charge linked to a recent transaction.
The company now expects its profits adjusted in 2025 to be between $ 8.82 and $ 8.97, slightly down compared to a previous perspective of $ 8.88 to $ 9.03 per share.
The company said that the expected tariff burden mainly reflects the samples between the United States and China, and Canada and Mexico to a lesser extent. Merck has built a solid presence in China, which is considered one of the most important markets in the company and houses some of its partners and research and research and development sites.
Merck has noted that the new perspectives do not take into account President Donald Trump’s planned rates on pharmaceutical products imported into the United States, which encourages some manufacturers to strengthen their American manufacturing footprints.
This includes Merck, who has invested $ 12 billion in American manufacturing and research and development and plans to put more than $ 9 billion more in the country by the end of 2028.
During a call for results Thursday, Merck’s CEO Rob Davis said that “looking at 2025, we are well positioned with the inventory to be able to mitigate everything we could see in the short term.” He added that at a long -term medium, “we have already started to identify where we can either reposition our own manufacturing”, which could resemble the modification of the priorities of existing factories, or to make external manufacturing in “bridge gaps” and to further develop internal production.
“In many ways, we are aligned with what the administration wants to do, and we believe that we are able to do it quite effectively,” he said.
The new guidelines include a single charge of around 6 cents per share linked to the company’s license agreement with Hengrui Pharma, which she announced in March.
Merck reiterated its sales forecasts in full year between $ 64.1 billion and $ 65.6 billion.
Also on Thursday, the drug manufacturer declared income and profits from the first quarter that beat expectations because he said he had had a force in his oncology portfolio and animal health products.
Merck also cited the “increasingly significant” sales contributions from two recently launched drugs. It is Winrevair, which is used to treat a rare and deadly pulmonary condition, and capvaxive, a vaccine designed to protect adults from a bacteria known as pneumococcus which can cause serious illnesses and pulmonary infection.
Sales of these drugs will probably be essential to Merck’s efforts to compensate for the losses of his best -selling Keytruda cancer therapy, who will lose exclusivity in 2028.
Here is what Merck has reported for the first quarter of what Wall Street was waiting, on the basis of a survey of LSEG analysts:
- Profit by action: $ 2.22 adjusted vs $ 2.14 expected
- Income: $ 15.53 billion against $ 15.31 billion expected
The company posted a net profit of $ 5.08 billion, or $ 2.01 per share, for the quarter. This is compared to the net income of $ 4.76 billion, or $ 1.87 per share, during the annual period.
By excluding acquisition and restructuring costs, Merck won $ 2.22 per share for the first quarter.
Merck collected $ 15.53 billion in revenue for the quarter, down 2% compared to the same period a year ago.
Pharmaceutical sales, animal health
The pharmaceutical unit of Merck, which develops a wide range of drugs, reserved $ 13.64 billion in revenues during the first quarter. It is down 3% compared to the same period a year ago.
Keytruda recorded $ 7.21 billion in revenue during the quarter, up 4% compared to the annual period.
This increase was motivated by a higher absorption of Keytruda for cancers at an anterior stage and a high demand for medication for metastatic cancers, which spread to other parts of the body. However, sales exceeded 7.43 billion dollars that analysts expected, stretaccount estimates.
In particular, Merck has continued to see trouble with sales in China from Gardasil, a vaccine that prevents HPV cancer, sexually transmitted infection in the United States
In February, Merck announced the decision to stop the Gardasil expeditions to China from this month and spend at least mid-201. Investors will likely look for updates to this effort when calling the profits on Thursday.
The Chinese market is the majority of international revenues of the blockbuster. Merck hopes that the extended approval of Gardasil for men aged 9 to 26 in China will help increase the adoption of the vaccine.
Gardasil collected $ 1.33 billion in sales, down 41% compared to the first quarter of 2024, mainly due to the drop in demand in China. It was below the $ 1.45 billion that analysts were waiting for, according to Streetaccount estimates.
China retaliated with 125% tariffs on the United States goods, some experts said that China’s prices on American products could cause prices or a limited offer of certain Popular Western drugs for Chinese patients, Reuters reported.
The Merck animal health division, which develops vaccines and dogs for dogs, cats and livestock, posted nearly $ 1.59 billion in sales, up 5% compared to the same period a year ago. The company said that the higher demand for farming and sales products from the Elanco Aqua company, which it acquired last year, led this growth.